InvestorsObserver
×
News Home

Altimmune Inc (ALT) has risen 12.29% in a Week, Should You Buy?

Thursday, March 28, 2024 12:02 PM | InvestorsObserver Analysts

Mentioned in this article

Altimmune Inc (ALT) has risen 12.29% in a Week, Should You Buy?

Altimmune Inc (ALT) is around the top of the Biotechnology industry according to InvestorsObserver. ALT received an overall rating of 81, which means that it scores higher than 81 percent of all stocks. Altimmune Inc also achieved a score of 95 in the Biotechnology industry, putting it above 95 percent of Biotechnology stocks. Biotechnology is ranked 19 out of the 148 industries.

Overall Score - 81
ALT has an Overall Score of 81. Find out what this means to you and get the rest of the rankings on ALT!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Altimmune Inc Stock Today?

Altimmune Inc (ALT) stock is trading at $10.23 as of 11:51 AM on Thursday, Mar 28, an increase of $1.31, or 14.74% from the previous closing price of $8.89. The stock has traded between $8.84 and $10.28 so far today. Volume today is light. So far 3,878,729 shares have traded compared to average volume of 5,560,224 shares. Click Here to get the full Stock Report for Altimmune Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App